Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Sponsor: Stanford University
Summary
The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.
Official title: Impact of Collagen VII Gene Therapy on Squamous Cell Carcinoma Recurrence in Recessive Dystrophic Epidermolysis Bullosa Skin
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2025-03-28
Completion Date
2027-02
Last Updated
2025-04-16
Healthy Volunteers
No
Conditions
Interventions
BVEC
The study drug will be administered by home nurse at Subjects home for the participants residing in US. No drug will be applied when at study site. The subjects enrolled in Bari, Italy will not be administered BVEC.
Locations (2)
Stanford University
Redwood City, California, United States
Azienda Ospedliero-Universitaia
Bari, Italy